undefined undefined undefined
Impact of 2nd-generation versus 3rd-generation beta-blockers on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range LVEF
Event: ESC Congress 2025
Topic: Epidemiology, Prognosis, Outcome
Session: Pharmacotherapy in coronary artery disease (1)
Impact of Nebivolol versus Carvedilol on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range left ventricular ejection fraction (40% to 49%)
Event: ESC Congress 2025
Topic: ST-Elevation Myocardial Infarction (STEMI)
Session: Pharmacotherapy in acute coronary syndromes (4)
Impact of 2nd-generation versus 3rd-generation beta-blocker prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents
Event: ESC Congress 2025
Topic: Epidemiology, Prognosis, Outcome
Session: Expanding pharmacological and non-pharmacological options for coronary disease
Impact of beta-blocker prescription at discharge on long-term clinical outcomes in ST elevation myocardial infarction patients with preserved LVEF and successful drug-eluting stent implantation
Event: ESC Congress 2025
Topic: Beta-Blockers
Session: Beta-blockers: traditional drugs opening new avenues
Impact of beta-blocker Nebivolol versus Carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents
Event: ESC Congress 2025
Topic: ST-Elevation Myocardial Infarction (STEMI)
Session: Pharmacotherapy in acute coronary syndromes (1)
